The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal malignancies. Cancer stem cells (CSCs), which are not targeted by current therapies, may be the reason for pronounced therapy resistance. A new treatment option in phase II trials is cabozantinib that inhibits the pancreatic CSC surfac...

Descripción completa

Detalles Bibliográficos
Autores principales: Hage, C, Rausch, V, Giese, N, Giese, T, Schönsiegel, F, Labsch, S, Nwaeburu, C, Mattern, J, Gladkich, J, Herr, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674365/
https://www.ncbi.nlm.nih.gov/pubmed/23661005
http://dx.doi.org/10.1038/cddis.2013.158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674365/
https://www.ncbi.nlm.nih.gov/pubmed/23661005
http://dx.doi.org/10.1038/cddis.2013.158

Ejemplares similares